Laura Marandino
University of Milan
Internal medicineRadiologyOncologyStage (cooking)Adverse effectClinical endpointCystectomyChemotherapyPenile cancerImmunotherapyInguinal lymph nodesPembrolizumabProstate cancerBladder cancerSalvage therapyLymph nodePenile squamous cell carcinomaPopulationMetastatic Urothelial CarcinomaPhase iii trialsMuscle invasiveIn patientCancer researchClinical trialMedicineBiomarker (medicine)
Publications 81
#1Lee A. HugarH-Index: 6
Last. Juan ChipolliniH-Index: 12
view all 26 authors...
#1Filippo PederzoliH-Index: 13
#2Irene LocatelliH-Index: 7
Last. Dejan LazarevicH-Index: 24
view all 17 authors...
#1Catherine Curran (Harvard University)H-Index: 5
#2Elio Adib (Harvard University)H-Index: 2
Last. Andrea Necchi (UniSR: Vita-Salute San Raffaele University)H-Index: 13
view all 14 authors...
ABSTRACT null null Background null Enfortumab vedotin (EV) is approved to treat metastatic urothelial carcinoma (mUC) following platinum and PD1/L1 inhibitors. Since the outcomes and patterns of therapy of patients following discontinuation of EV are unknown, we conducted a retrospective study to assess this issue. null null null Methods null Data were retrospectively obtained from patients with mUC following discontinuation of EV after prior platinum-based chemotherapy and PD1/L1 inhibitors. Ob...
#1Andrea Necchi (UniSR: Vita-Salute San Raffaele University)H-Index: 13
#2Joep J. de Jong (EUR: Erasmus University Rotterdam)H-Index: 7
Last. Ewan A. GibbH-Index: 27
view all 16 authors...
Abstract Background In patients with muscle-invasive urothelial bladder cancer (MIBC), molecular alterations in immunotherapy-resistant tumors found at radical cystectomy (RC) remain largely unstudied. Objective To investigate the biology of pembrolizumab-resistant tumors in comparison to an RC cohort treated without any systemic therapy and a cohort of neoadjuvant chemotherapy (NAC)-treated tumors. Design, setting, and participants Transcriptome-wide expression profiling was performed on 26 RC ...
1 CitationsSource
#1Andrea Necchi (UniSR: Vita-Salute San Raffaele University)H-Index: 13
#2Daniele Raggi (University of Milan)H-Index: 19
Last. Yair Lotan (UTSW: University of Texas Southwestern Medical Center)H-Index: 107
view all 11 authors...
Abstract null null Purpose null Clinical high-grade (HG) T1 non-muscle invasive bladder cancer (NMIBC) represents a significant risk to patients, but these patients are not typically offered neoadjuvant therapies, including immune therapy. In this study, we determine whether patients with HG clinical T1 or T2 bladder urothelial carcinoma (UC) have profiles that predict the potential effectiveness of immune-checkpoint inhibitors (ICI). null null null Materials and Methods null Data from transuret...
#1Laura MarandinoH-Index: 10
#2Andrea Necchi (UniSR: Vita-Salute San Raffaele University)H-Index: 13
#1Andrea NecchiH-Index: 35
#2Laura MarandinoH-Index: 10
Last. Francesco Montorsi (UniSR: Vita-Salute San Raffaele University)H-Index: 138
view all 8 authors...
The similar clinical behavior, overlapping therapeutic patterns, and several clinical trials addressing the neoadjuvant and first-line therapy settings for bladder cancer support the call for a more uniform definition of "locally advanced" disease. We highlight the diverse therapeutic opportunities that patients with locally advanced bladder cancer may receive at present. Multimodal management, and post-therapy surgery in particular, may still have a role in selected patients.
2 CitationsSource
#1Andrea NecchiH-Index: 13
#2J.J. De JongH-Index: 1
Last. U. CapitanioH-Index: 3
view all 16 authors...
#1Filippo Pederzoli (UniSR: Vita-Salute San Raffaele University)H-Index: 13
#2Marco Bandini (UniSR: Vita-Salute San Raffaele University)H-Index: 24
Last. Andrea Necchi (UniSR: Vita-Salute San Raffaele University)H-Index: 13
view all 12 authors...
In locally advanced and metastatic malignancies, antibiotic (ATB) therapy has a negative effect on immunotherapy efficacy. Therefore, we aimed to evaluate whether ATB therapy and use of specific ATB classes with concomitant neoadjuvant pembrolizumab affected pathologic complete response (ypT0N0) and relapse-free survival (RFS) for patients with clinical T2-4N0M0 bladder cancer enrolled in the PURE-01 study. Of the 149 patients evaluated, 48 (32%) received any concomitant ATB therapy. The ATB cla...
#2Aaron Dahmen (USF: University of South Florida)H-Index: 1
Last. Philippe E. SpiessH-Index: 35
view all 22 authors...
PURPOSE Our primary objective is to detail the incidence, site, and timing of pSCC recurrence after ILND. METHODS Retrospective analysis of 551 patients who underwent ILND for pSCC, from 2000 to 2017. The primary outcome was pSCC recurrence after ILND. Recurrences were identified and stratified by site. Timing of recurrence was determined. Multivariable logistic regression analysis determined associations with recurrence. Multivariable Cox regression analysis determined associations with overall...